Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide - PubMed
6 hours ago
- #Salvage Therapy
- #T-cell Engagers
- #Multiple Myeloma
- Multiple myeloma (MM) is an incurable hematologic malignancy characterized by clonal plasma cell proliferation.
- Cellular therapies like CAR-T and T-cell engagers (TCEs) show high response rates but most patients relapse.
- A retrospective study of 12 MM patients treated with talquetamab, elranatamab, or teclistamab combined with pomalidomide showed 11/12 responses, with 6 achieving very good partial response or better.
- All patients had prior pomalidomide exposure, and 10 had prior CAR-T therapy, with a median of 7 prior lines of therapy.
- Safety profiles were manageable, with Grade 1 CRS in 6 patients, Grade III neutropenia in 7, and on-target, off-tumor effects like dysgeusia in talquetamab-treated patients.